0620/24SCR019-18/R10
Media Highlights
From the 2024 ASCO® Annual Meeting
5
Continued ➔
Media Outlet Article / Coverage
AJMC Osimertinib Offers 84% Improvement in PFS Over Standard of
Care in Stage III Unresectable EGFR-Driven NSCLC
American Cancer Society Targeted Cancer Drug Lowers Risk of Cancer Growth or Death in
Lung Cancer with a Specific Mutation
Barron's Pfizer Drug Extends Life For People With Rare Form of
Lung Cancer
BioPharmaDive Astrazeneca Immunotherapy Extends Survival by Two Years
in Rarer Type of Lung Cancer
Business Times Pfizer's Lung Cancer Drug Shows Unprecedented Long-
Term Efficacy
Cancer Health Lorbrena Yields "Unprecedented" Progression-Free Survival
for ALK-Positive Lung Cancer
CancerNetwork Consolidation Durvalumab Significantly Improves Survival in
LS-SCLC
CancerNetwork Osimertinib Improves PFS in Advanced EGFR+ NSCLC
CNBC Healthy Returns: Drugmakers Release Promising Cancer
Drug Data – And Astrazeneca Wins Big
CNBC Pfizer's Drug for Advanced Lung Cancer Shows Pomising
Long-Term Trial Results
David Spigel, MD
SCRI
Media Outlet Article / Coverage
AJMC No CRS Seen in First 10 Patients in Teclistamab Pilot With
Prophylactic Tocilizumab
Oncology Learning Network Prophylactic Tocilizumab Prior to Outpatient Step-Up
Administration of Teclistamab Lowers CRS Among Patients
With R/R MM
HemOncToday Regimen Confers 'Clinically Meaningful' PFS Benefit in
Relapsed Multiple Myeloma
Robert Rifkin, MD
SCRI at Rocky Mountain Cancer Centers
